$RCEL

Woody Joseph Fralin purchased $21K of RCEL

Woody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.21 on 2026-06-02.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 3, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RCEL
Bullish
medium confidence
Mentioned
$RCEL
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

The disclosed open-market purchase increases the director’s direct holdings to 20,000 shares, which can be sentiment-supportive but is not a fundamental update.

02

Market read

A director’s open-market buy is a modest positive signal for RCEL sentiment, with limited trading edge absent additional catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no rationale for the purchase or whether it was part of broader insider activity.

Relevance 7/10Novelty 5/10Timing: After-hours/filing day disclosure on 2026-06-03 for a 2026-06-02 purchase.

Background

This is an SEC Form 4 insider transaction disclosure for Avita Medical, Inc. (RCEL).

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

Avita Medical director Woody Joseph Fralin bought 5,000 shares of RCEL in an open-market transaction disclosed on Form 4.

Expected impact

Limited near-term impact; any effect is likely small and short-lived unless followed by additional disclosures or fundamentals.

Evidence & confidence

The filing provides a concrete ownership change (buy) but no accompanying company-specific operational or financial update.

Market effects

No clear sector read-through from a single insider buy without additional context.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (e.g., liquidity planning) and may not signal a change in near-term fundamentals.

Key entities

  • Woody Joseph Fralin

    Director of Avita Medical who reported an open-market purchase of 5,000 RCEL shares.

  • Avita Medical, Inc.

    RCEL issuer; subject of the Form 4 insider transaction.

Related articles

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

$RCELHigh

AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a